stockrow
Saturday 7 November 2026
Export DNA’s income statement to Excel — free account
Ginkgo Bioworks Holdings, Inc.
Ginkgo Bioworks Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $170.2 million, down 25.1% from fiscal 2024.
- Revenue
- −59.4%
- EPS
- +31.8%
- Free cash flow
- −16.4%
Quarter to June 2026, against a year earlier
11.19
1.23
+12.35%
Follow DNA
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
3 | 4 | 3 | 4 |
+8 more TTM periods Free account |
| (56.29%) | (55.82%) | (51.08%) | (50.02%) | ||
| (26.19%) | (26.17%) | (25.05%) | (25.43%) | ||
ROIC |
(161.94%) | (274.12%) | (229.21%) | (212.39%) | |
Return on Tangible Assets |
(69.74%) | (61.70%) | (57.57%) | (59.84%) | |
Average Days of Receivables |
42.46 | 52.35 | 52.03 | 45.19 | |
Free Cash Flow per Share |
(2.81) | (2.81) | (3.21) | (3.36) | |
Free Cash Flow |
(174.23) | (167.63) | (178.15) | (187.13) | |
Capital Expenditures |
(3.98) | (1.40) | (7.09) | (21.31) | |
| Other line items | |||||
Cash ROIC |
(24.12%) | (20.53%) | (19.13%) | (18.32%) | |
Accounts Receivable Turnover |
6.19 | 5.96 | 7.29 | 7.80 | |
Accounts Payable Turnover |
4.07 | 3.33 | 3.80 | 2.42 | |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
82.58 | 129.46 | 82.10 | 122.50 | |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
192.74% | 157.65% | 143.27% | 149.51% | |
Selling, General and Administrative Expense of Revenue |
158.40% | 128.37% | 107.72% | 97.98% | |
Share Based Compensation of Revenue |
61.51% | 56.62% | 47.92% | 44.89% | |
Operating CF/Net income |
0.59 | 0.55 | 0.55 | 0.49 | |
Depreciation/Fixed assets |
0.32 | 0.33 | 0.33 | 0.35 | |
Capex/Depreciation |
(0.08) | (0.03) | (0.13) | (0.35) | |
Revenue per Share |
1.80 | 2.37 | 3.07 | 3.25 | |
Operating CF per Share |
(2.74) | (2.79) | (3.08) | (2.98) | |
Capex per Share |
(0.06) | (0.02) | (0.13) | (0.38) | |
Capex to Sales |
0.04 | 0.01 | 0.04 | 0.12 |
Columns are period end dates · fundamentals updated 26 Oct 2026